New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
08:03 EDTAMPELuoxis obtains CE Marking for RedoxSYS diagnostic system
Ampio announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in market development activities designed to establish the clinical utility of the RedoxSYS System in the critical care setting, and position the company for a successful launch in Europe, which is currently anticipated for 2015.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
18:18 EDTAMPERosewind acquires ProstaScint assets from Jazz Pharmaceuticals
In a regulatory filing earlier, Ampio Pharmaceuticals (AMPE) reported that on May 20, Rosewind, an approximately 81.5%-owned subsidiary of Ampio, entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals (JAZZ). Pursuant to the agreement, Rosewind purchased assets related to ProstaScint, or capromab pendetide, including certain intellectual property and contracts, and the product approvals, inventory and work in progress, and assumed certain of Jazz's liabilities, including those related to product approvals and the sale and marketing of ProstaScint. Rosewind paid $1M at closing for the ProstaScint assets. Rosewind has also agreed to pay an additional $500,000 within five days after transfer for the ProstaScint-related product inventory, and $226,523 payable on September 30, which represents a portion of certain United States Food and Drug Administration fees. Rosewind also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of $2.5M. The agreement also provides that for a period of one year, Jazz agrees to not directly or indirectly, through any of its agents or affiliates, compete against ProstaScint, or acquire a company or business in which more than 15% of such acquired business’ total revenue is generated by products that compete with ProstaScint.
May 21, 2015
15:57 EDTAMPEAmpio says Optina benefit not significant vs. placebo, Bloomberg reports
Vaughan Lennox Clift, Chief Regulatory Affairs Officer of Ampio, told Bloomberg in a phone interview that Optina's benefit is not significant versus the placebo. Optina helped a group improve from baseline, Bloomberg adds. Clift also said the FDA may allow narrow sales with a post-market study.
08:08 EDTAMPEAmpio announces positive study results on Optima
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use